Gufic BioSciences Ltd
Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.
- Market Cap ₹ 3,526 Cr.
- Current Price ₹ 352
- High / Low ₹ 504 / 285
- Stock P/E 57.0
- Book Value ₹ 59.9
- Dividend Yield 0.03 %
- ROCE 13.2 %
- ROE 12.3 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 5.87 times its book value
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|
807 | 820 | 841 | |
657 | 684 | 708 | |
Operating Profit | 150 | 136 | 132 |
OPM % | 19% | 17% | 16% |
-0 | 4 | 3 | |
Interest | 17 | 25 | 28 |
Depreciation | 17 | 21 | 24 |
Profit before tax | 116 | 94 | 83 |
Tax % | 26% | 26% | |
86 | 70 | 62 | |
EPS in Rs | 8.59 | 6.95 | 6.17 |
Dividend Payout % | 1% | 1% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 3% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -28% |
Stock Price CAGR | |
---|---|
10 Years: | 24% |
5 Years: | 32% |
3 Years: | 19% |
1 Year: | -19% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2024 | Mar 2025 | |
---|---|---|
Equity Capital | 10 | 10 |
Reserves | 523 | 591 |
333 | 336 | |
227 | 232 | |
Total Liabilities | 1,093 | 1,169 |
159 | 506 | |
CWIP | 307 | 22 |
Investments | 2 | 2 |
625 | 640 | |
Total Assets | 1,093 | 1,169 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2024 | Mar 2025 | |
---|---|---|
-7 | 123 | |
-102 | -71 | |
82 | -37 | |
Net Cash Flow | -27 | 15 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2024 | Mar 2025 | |
---|---|---|
Debtor Days | 149 | 140 |
Inventory Days | 188 | 211 |
Days Payable | 156 | 155 |
Cash Conversion Cycle | 181 | 197 |
Working Capital Days | 97 | 93 |
ROCE % | 13% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
4m - Newspaper Advertisement regarding 100 days campaign - "Saksham Niveshek" is attached herewith.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Oct - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2025 is attached herewith
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
30 Sep - 41st AGM Sep 29, 2025: seven resolutions passed; final dividend Re.0.10/share; consolidated scrutinizer report.
- Shareholder Meeting / Postal Ballot-Outcome of AGM 29 Sep
-
Closure of Trading Window
26 Sep - Trading window closed Oct 1, 2025 until 48 hours after unaudited results for quarter/H1 ended Sep 30, 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
Concalls
-
Aug 2025Transcript PPT
-
Jun 2025Transcript PPT
-
May 2025TranscriptNotesPPTREC
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
Jun 2024TranscriptPPT
-
May 2024TranscriptPPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022TranscriptPPT
-
Feb 2022TranscriptPPT
-
Nov 2021Transcript PPT
-
Aug 2021TranscriptPPT
-
Jun 2021Transcript PPT
-
Nov 2020TranscriptNotesPPT
Business Segments
1) Domestic Branded Business: The company develops pharmaceutical formulations in various forms, including injectables, syrups, ointments, lotions, and herbal products. It serves 15+ therapeutic areas, including critical care, infertility, nutraceuticals, etc with a portfolio of 100+ products, 200+ SKUs, and a network of 30,000+ prescribers. It is one of the largest manufacturers of Lyophilized Injections in India. The company aims to expand into Biologicals and Immuno-Oncology. [1] [2]